DTC
NRIX icon

Deep Track Capital’s Nurix Therapeutics NRIX Stock Holding History

Deep Track Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.4M Sell
6,345,244
-691,211
-10% -$11.5M 1.61% 19
2025
Q4 		$133M Buy
7,036,455
+979,431
+16% +$14.1M 2.38% 15
2025
Q3 		$56M Sell
6,057,024
-7,886
-0.1% -$81.9K 1.56% 21
2025
Q2 		$69.1M Buy
6,064,910
+564,910
+10% +$6.1M 2.22% 17
2025
Q1 		$65.3M Buy
5,500,000
+2,500,000
+83% +$41.8M 2.12% 16
2024
Q4 		$56.5M Sell
3,000,000
-868,104
-22% -$19.9M 2.11% 13
2024
Q3 		$86.9M Sell
3,868,104
-123,396
-3% -$2.8M 2.76% 14
2024
Q2 		$83.3M Buy
3,991,500
+993,670
+33% +$15.5M 2.49% 17
2024
Q1 		$44.1M Hold
2,997,830
– – 1.26% 31
2023
Q4 		$30.9M Hold
2,997,830
– – 1.03% 39
2023
Q3 		$23.6M Hold
2,997,830
– – 0.91% 34
2023
Q2 		$29.9M Hold
2,997,830
– – 1.39% 22
2023
Q1 		$26.6M Buy
2,997,830
+731,261
+32% +$7.62M 1.09% 32
2022
Q4 		$24.9M Buy
2,266,569
+212,948
+10% +$2.57M 1.04% 35
2022
Q3 		$26.8M Sell
2,053,621
-382,543
-16% -$6.05M 1.23% 31
2022
Q2 		$30.9M Buy
+2,436,164
New +$27.6M 2.03% 20

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deep Track Capital's NRIX Position: Q1 2026 in Review

Deep Track Capital reduced its Nurix Therapeutics (NRIX) stake by 9.8% in Q1 2026, selling an estimated $11.5M and leaving 6,345,244 shares worth $98.4M. The position accounts for 1.61% of the portfolio, ranked #19.

Deep Track Capital first reported a position in NRIX in Q2 2022 and has held it in 16 quarters since. The position peaked at $133M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Deep Track Capital held 6,345,244 shares of Nurix Therapeutics worth $98.4M as of Q1 2026.
  • Deep Track Capital sold 691,211 Nurix Therapeutics shares in Q1 2026, an estimated $11.5M.
  • Nurix Therapeutics made up 1.61% of Deep Track Capital's portfolio in Q1 2026, its #19 holding.
  • Deep Track Capital first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Deep Track Capital's Nurix Therapeutics position peaked at $133M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.